BriaCell closes $5.55M public offering of 7.4M units at $0.75/unit

BriaCell Therapeutics Corp.

Underwritten public offering of 7,400,000 units closed Dec 13, 2024; gross proceeds $5.55M.
Each unit: 1 common share + 1 warrant exercisable at $0.9375 for 5 years.
Underwriter ThinkEquity received 370,000 representative's warrants on same terms.
Net proceeds to be used for working capital, general corporate purposes, and business advancement.
Offering made under effective shelf registration statement (S-3 No. 333-276650).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.